whatsapp With time running out before the “crunch” EU summit which begins on Thursday, it appears likely that the UK will not get a Free Trade Agreement (FTA) anywhere near as good as Canada did. In fact, if the Withdrawal Agreement and the Northern Irish Protocol are retained, a trade agreement with the EU as favourable as Canada’s would be virtually impossible. Alas, it is beginning to look like tearing up the Withdrawal Agreement and walking away might be the best approach. Unless major concessions are made by the EU on a number of significant areas in the final moments, a no-deal Australian-style Brexit may be better than the inevitable Canada-minus disappointment. Moreover, while Ceta allows for normal remedies for a breach (the suspension of tariff concessions) as well as a continued role for the WTO courts, the Withdrawal Agreement permits the enforcement of arbitral awards and ECJ judgments by monetary penalties and precludes access to WTO dispute settlement. These are very harsh — and unfriendly — terms indeed. Main image credit: Getty More From Our Partners Brave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgI blew off Adam Sandler 22 years ago — and it’s my biggest regretnypost.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comConnecticut man dies after crashing Harley into live bearnypost.com‘Neighbor from hell’ faces new charges after scaring off home buyersnypost.comBiden received funds from top Russia lobbyist before Nord Stream 2 giveawaynypost.comMark Eaton, former NBA All-Star, dead at 64nypost.comKiller drone ‘hunted down a human target’ without being told tonypost.comMatt Gaetz swindled by ‘malicious actors’ in $155K boat sale boondogglenypost.comUK teen died on school trip after teachers allegedly refused her pleasnypost.com980-foot skyscraper sways in China, prompting panic and evacuationsnypost.comWhy people are finding dryer sheets in their mailboxesnypost.com The tone, attitude, and framing around these negotiations are also markedly different. For Canada, Ceta was simply a normal international treaty, ratified by a domestic statute which conforms to the Canadian Constitution. Not so for the future UK-EU FTA, since the Withdrawal Agreement is to be considered supreme over all UK law. There had been high hopes that the EU would offer the UK something special on trade because Britain and Europe are “old friends”. This is not to say that Canada and the EU were enemies — as a Canadian myself, I know that they are strong allies. But Canada was never part of the family with a common history of regulatory alignment, nor does Canada rely so heavily on the EU for trade (and vice versa) as the UK does. Opinion The most well-known of these relates to state aid. The Withdrawal Agreement requires the UK to remain aligned with EU’s strict rules on government support for ailing industries. Ceta contained no such obligation, sticking to normal WTO-style subsidies disciplines. The UK also remains subject to the European Court of Justice (ECJ) on state aid matters, whereas the ECJ plays no role in Ceta, since Canada is a country which staunchly defends its sovereignty both in terms of legislation and its judiciary. With friends likes these… the UK is better off walking away than signing up to an EU deal When it comes to Brexit deals, Australia may be a lot further away from the EU than Canada — but right now, it’s looking a fair sight better. The second most pressing of the Brexit issues — fishing — is also omitted from Ceta, leaving Canadian waters exclusively under Ottawa’s control. When it comes to the UK, however, the EU has made fishing access in UK waters going forward one of its reddest red lines. A new report co-authored by me for the Centre for Brexit Policy, entitled “The EU Deal Unmasked: Twelve Reasons Why the UK Will Fail to Get a Canada-Style Deal”, explains how, the way things are going, a UK-EU FTA is more likely to be Canada-minus than Canada-plus. whatsapp City A.M.’s opinion pages are a place for thought-provoking views and debate. These views are not necessarily shared by City A.M. Show Comments ▼ Accordingly, there is no requirement for any of Canada’s provinces to be carved off from the rest of the Confederation, subject to a separate regime of control by a foreign state which does not apply elsewhere in the country. Notoriously, the Northern Ireland Protocol does just that to the UK. The protocol also mandates tariffs and regulatory checks on an internal border within the UK — something which would never be permitted under the Canadian Constitution with respect to inter-provincial trade. Sometimes old friends become the worst enemies. Far from a Canada-plus arrangement, which the UK might have legitimately expected given its close ties with the EU and shared regulatory past, the FTA offer the UK is likely to get from Brussels will be inferior in many crucial ways. David CollinsDavid Collins is professor of international economic law at City University Canada-plus? More like Canada-minus (POOL/AFP via Getty Images) Also Read: With friends likes these… the UK is better off walking away than signing up to an EU deal Canada-plus? More like Canada-minus (POOL/AFP via Getty Images) by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeDaily FunnyFemale Athlete Fails You Can’t Look Away FromDaily Funnybonvoyaged.comTotal Jerks: These Stars Are Horrible People.bonvoyaged.comPast Factory”Waltons” Actress Says Magazine Ended Her CareerPast FactoryFinanceChatterViewers Had To Look Away When This Happened On Live TVFinanceChatterNoteableyAirport Security Couldn’t Believe These Jaw-Dropping MomentsNoteableyinvesting.comThe Military Spent $1 Billion On this New Vehicle, And Here’s The First Lookinvesting.comPost Fun25 Worst Movies Ever, According To Rotten TomatoesPost FunJustPerfact USAMan Decides to File for Divorce After Taking a Closer Look at This Photo! JustPerfact USAThe Chef PickElisabeth Shue, 57, Sends Fans Wild As She Flaunts Age-Defying FigureThe Chef Pick Share Tuesday 13 October 2020 4:26 am The Comprehensive Economic and Trade Agreement (Ceta) which the EU signed with Canada in 2017 provides for many benefits which almost certainly will be missing from a UK-EU FTA. Sadly, these expectations were misplaced. The EU has even refused to recognise product testing by UK bodies for conformity with its standards, despite the fact that these bodies not only have their own robust reputations but have followed EU standards historically, and will do so for the foreseeable future. Yet this recognition was extended to unproven Canadian testing authorities under Ceta. Canada-plus? More like Canada-minus (POOL/AFP via Getty Images) Also Read: With friends likes these… the UK is better off walking away than signing up to an EU deal
Local GovernmentReport: Revenue at Juneau’s city-run pools up 38 percentJune 28, 2016 by Lakeidra Chavis, KTOO Share:Aquatics Board Chair Max Mertz presents the annual report to the Juneau Assembly. (Photo by Lakeidra Chavis/ KTOO)The city’s Aquatics Board presented its first annual report to the Juneau Assembly on Monday.The assembly created the board last spring to improve the quality of service at the city’s two swimming pools — the Augustus Brown Swimming Pool downtown and the Dimond Park Aquatic Center in the valley.Board chair Max Mertz told the assembly that the group has made a lot of progress in their first year. Some of the changes they’ve made include reducing the cost of annual passes and allowing customers to use their passes at both city pools.“We’ve had pretty stunning success, honestly,” Mertz says. “This year compared to last year, since the new rates were implemented, we’re about 38 percent up on revenue.”According to the report, the pools recover a nearly a third of the more than $2 million it takes to run them. Mertz hopes the board can increase that within the next two years. Food services and partnerships with larger organizations are part of the plans.“We want to figure out a way that we can market the pools for corporations in such a way that it makes sense for them to buy passes for their employees and use the pools,” he said.The board is set to sunset in spring of 2018. Until then, Mertz says the seven-member group will continue to find ways to improve the city’s aquatics services in staffing, cost recovery and customer satisfaction.Correction: An earlier version of this story misstated the increase in revenue. Share this story:
Juneau | Public Safety | TransportationTraffic engineers back $34M highway interchange at accident-prone Juneau intersectionNovember 5, 2019 by Jeremy Hsieh, KTOO Share:In a 210-page report about the accident-prone intersection of Egan and Yandukin drives in Juneau, Kinney Engineering illustrated how it could be rebuilt as a highway interchange. (Courtesy Alaska Department of Transportation & Public Facilities)Traffic engineers are recommending rebuilding an accident-prone intersection in Juneau as a highway interchange. Meaning a pair of new on-ramps and off-ramps, and an overpass.At $34 million, it’s the most expensive of the options the consultants analyzed. But it was also the only option that improved both overall safety and traffic flow around the intersection near Fred Meyer.The state Department of Transportation and Public Facilities published Kinney Engineering’s report on the intersection Monday on its website. The recommendation is just one early step in the department’s process to prioritize and select projects.Juneau resident Erik Stimpfle said he was nearly rear-ended there on Monday evening. He said he was getting onto Egan Drive with his family. His wife noticed the driver behind him wasn’t slowing down.“We were just right at the end of the merge lane, and they were not letting us in,” he said. “I was already going 50 (mph), but I stayed in the emergency lane until they went by.”As the driver passed, he said he honked on the horn really hard.However, it’s failed left turns across oncoming traffic that tend to result in the most severe crashes.The 210-page report gets into some pretty cold statistical analysis. For example, it applies state and federal transportation methodologies to assign dollar values to drivers’ time lost to traffic delays, as well as property damage, injuries — even fatalities.Other options they considered created traffic delays and made accidents more likely elsewhere, though at lower speeds.The other options were:no change;installing a traffic light; andblocking left turns in the intersection, but creating similar access by extending the Glacier Highway dead end behind Fred Meyer into the traffic light at the “McNugget” intersection of Egan Drive and Glacier Highway.That last option was popular at an open house the Department of Transportation held in December 2017.The report’s crash analysis also undercuts some assertions that this is Juneau’s — or even Alaska’s — most dangerous intersection. The consultants found the crash rate is comparable to other intersections of this type around Alaska. They did find the severity of the crashes was above average, but not exceptional.The Department of Transportation has scheduled an open house about the intersection from 4-7 p.m. on Nov. 19 in the community room at the Nugget Mall.Collision near Juneau’s Fred Meyer causes multiple injuriesShare this story:
© Ian Wilson The second announcement revealed a partnership between Luxembourg Airport and Shanghai terminal operator Eastern Air Logistics (EAL) to implement a GDP-certified end-to-end trade lane.The agreement, signed at Air Cargo China in Shanghai last week, includes a commitment to maintain a fully GDP-secured trade lane for time and temperature-sensitive healthcare products between Luxembourg and Shanghai’s Hongqiao and Pudong airports.Lux-Airport chief executive Johan Vanneste said: “We signed a similar agreement last year with Hong Kong Air Cargo Terminals Limited (HACTL), and this was, we believe, the first time this was done in the world. Meanwhile I have discovered we have been copied a few times by certain airports and airline groups.”Laurent Jossart, executive vice-president LuxairCARGO, told The Coolstar that Hong Kong volumes have dramatically increased since they signed the agreement in May 2015.“We signed an agreement one year ago with HACTL and since then we experienced growth of more than 50% on that trade lane. So hopefully the agreement with Shanghai will similarly provide double-digit growth in the coming years.”An industry recognised pharma-handling certification is increasingly becoming a requirement rather than a luxury for air cargo players.Many airports and airlines have taken steps to become certified through either GDP or IATA’s CEIV programme, to convince shippers the temperature of their lucrative healthcare products will remain consistent and excursion-free when handled and transported by truck and by plane between Europe and Asia.For Mr Jossart, who noted Lux-Airport became GDP certified before CEIV existed, the former remains the preferred industry standard.“It’s much more important [than CEIV] because GDP is the initiative of the pharma shippers, we believe the shippers are setting the standards because they are paying for the transport. CEIV is an initiative by the airlines and by IATA.“We believe GDP was the right way to go, but should CEIV become market standard tomorrow, then I guess we might also adopt it but that’s not the case today and we still believe GDP is a much higher standard than CEIV, and so it was the right decision for us.”A spokeswoman for IATA, however, noted that GDP was in fact launched by regulatory authorities, and that CEIV includes all the relevant GDP standards, as well as additional ones.Asked whether temperature excursions had been reduced as a result of the HACTL agreement and GDP certification, Mr Jossart said the relevant data was not previously recorded and so it would be difficult to make a comparison, however he added that excursions are now being tracked.Meanwhile, Emirates SkyCargo is also hoping to boost its pharma cargo credentials by gaining GDP certification.Vice-president Ravi Mirle said: “25% of our volumes are now perishables and we are placing a lot of emphasis on pharma. Our cargo terminal in Dubai is going to be GDP certified in two months’ time and we are hopeful that will stimulate a lot of interest.” By Sam Whelan in Shanghai 21/06/2016 With competition for temperature-controlled pharmaceutical air cargo intensifying, initiatives to entice shippers with certified door-to-door trade lanes are gaining momentum. But not every company is a fan of IATA’s CEIV programme.Two initiatives were announced last week. In the first, Swiss WorldCargo, Cargologic and Singapore Airport Terminal Services (SATS) established a “secure temperature-controlled, quality corridor” between Singapore and Zurich.The three parties said they had synchronised cargo handling facilities and procedures to deliver accurate and reliable handling on the ground and in the air. Carologic and SATS are both certified to IATA CEIV and GDP standards.
Greenbriar Equity Group, owner of Seko Logistics, has invested $500m of Series A funding into Uber Freight.The investment values the US logistics arm of Uber at $3.3bn. Uber maintains majority ownership and will use the money to scale its logistics platform.It will “accelerate product innovation to equip shippers with technology to power their supply chains”, it says.Two Greenbriar managing partners will join Uber Freight’s board.“We are tremendously proud of what we have accomplished in a few short years,” said Lior Ron, head of Uber Freight.“We have led the industry with technology, transforming dated and analogue processes to ensure both shippers and carriers are equipped to succeed in a rapidly changing industry.”Michael Weiss, Greenbriar managing partner, added: “Uber Freight has created an innovative and effective approach to logistics technology that we believe is highly scalable in the coming years. In particular, we believe that carriers and shippers will be increasingly attracted to the convenience and simplicity that Uber Freight offers in a complex marketplace.“We are eager to share the extensive knowledge and expertise we have built through our decades-long involvement in the logistics sector.”Greenbriar has extensive investments in aerospace companies, as well as a GPS vehicle tracking company and LaserShip, a regional last-mile delivery company that serves the Eastern and Midwest US. It also owns Seko Logistics, although last year said it was selling its stake as part of a planned transition.Uber Freight recently signed new API integration partnerships with some of the largest cloud TMS providers, including SAP, Blue Yonder, BluJay, MercuryGate and Oracle. It also launched Uber Freight Enterprise and Uber Freight Link.Last month, digital freight forwarder Sennder bought Uber’s European freight business. © Dennizn By Alex Lennane 02/10/2020
About the Authors Reprints As vaccines start to roll out, the supply will be so limited that they’ll be used for frontline workers or people more vulnerable to Covid-19. But eventually, immunizations will be more widely available, and the majority of Americans will need to get vaccinated if the pandemic is going to draw to a close. Health authorities planning for the allocation and distribution of Covid-19 vaccines have been taking this into account as they’ve charted out their campaigns. There’s another piece of good news in just how effective the Pfizer and Moderna vaccines appear to be. Experts believe — and polling data supports — that reluctance to get vaccinated may abate in some quarters if the vaccines work well. The public has been more or less warned these vaccines might be flu vax redux — and at least half the public doesn’t think flu vax is worth getting. A highly efficacious vaccine bodes well for uptake. Helen Branswell and Matthew Herper contributed reporting. Adobe Are the two vaccines equally effective?It’s too early to tell for certain, but the overall efficacy of the vaccines appears to be similar, based on the data disclosed to date. This isn’t altogether surprising, since the Moderna and the Pfizer/BioNTech vaccine candidates are both based on the same kind of technology. advertisement For everyone else, neither vaccine is likely to be available until spring at the earliest, in large part because of logistics. (By that time, Pfizer and Moderna are also likely to have generated enough supporting data to justify full FDA approvals.) Pfizer and Moderna expect to produce just 70 million doses of their vaccines by the end of 2020, enough for only 35 million people around the globe. In 2021, the companies could have as many as 2.3 billion doses between them, but in a pandemic-ravaged world of 7.5 billion people, that’s not going to be enough to satisfy demand. Unless more Covid-19 vaccines prove to work in the coming months, the world will be rationing doses well into next year.Further complicating matters is the issue of storage. Pfizer is capable of manufacturing more doses than Moderna, but its vaccine must be shipped and stored at ultra-cold temperatures, which could make it difficult to deploy in parts of the world that lack specialized freezers. By contrast, Moderna said its vaccine can be safely stored in a conventional refrigerator. That sets up a short-term situation in which Pfizer’s vaccine is the most bountiful but Moderna’s is the most convenient, which will require some deft maneuvering on the part of global health agencies.Vaccines are important, but only if people get them.Public health experts are quick to tell you: Even the world’s best vaccine won’t do much unless people are willing to get it. This has been a particular concern with Covid-19 vaccines, as polls show that a substantial portion of Americans — whether because of how fast the process has moved or because of concerns that the vaccine review process would become politicized — said they would not get a Covid-19 vaccine when it became available. Skepticism about Covid-19 vaccines was even higher among people of color, who have experienced historic and ongoing mistreatment and discrimination in health care, and who are suffering from a disproportionate impact of the pandemic in the United States. Four reasons for encouragement based on Pfizer’s Covid-19 vaccine results @adamfeuerstein Based on data disclosed Monday, the Moderna vaccine appears to have been protective in important subsets of participants — the elderly and people from communities of color, the latter of which make up 37% of the volunteers in Moderna’s trial. Moderna also released data about the number of participants who developed severe Covid-19. There were 11 cases of severe disease, all of them in the placebo group. The elderly often respond less robustly to vaccines and are more vulnerable to having severe cases of Covid-19, if infected.The clinical trial conducted by Pfizer and BioNTech included the same subpopulations of participants, but specific results have not been disclosed.We don’t know how effective these vaccines are in the long-term.Some immunizations provide protection against a pathogen for decades (think the measles vaccine). It’s thought that the benefits of a Covid-19 vaccine — no matter the manufacturer — won’t last nearly as long. But researchers won’t know how long until the immunity offered by these vaccines begins to wear off. This will be something scientists keep an eye on in the months to come.“We do not know at this point what the durability of protection will be,” Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, said on a call with reporters Monday. How long vaccine-derived protection lasts has implications not only for manufacturing and how frequently people might be required to get boosters, but also for the ongoing risk of transmission of SARS-CoV-2. There are other unanswered questions about these vaccines as well. For one, the trials were designed primarily to look at the impact on symptomatic Covid-19. But experts will also want to see if the vaccine candidates can block infections entirely, or if they’re just making people less sick. Another: If people can still contract SARS-2 after getting vaccinated, are they less infectious to other people? The safety profile of the vaccines is encouraging, so far.So far, both vaccines appear to be generally tolerable — but by no means painless. In its announcement Monday, Moderna said it observed a few short-lived severe side effects in volunteers, including fatigue, muscle pain, and headache. None required hospitalization. For its part, Pfizer said last week that its independent data monitors reported no serious safety concerns. In an earlier update from its Phase 1 clinical trial, Pfizer’s vaccine led to mild or moderate fever and pain at the site of injection, side effects that resolved over time, the company said.But the most important safety data won’t come until patients have been followed for months and even years. Pfizer and Moderna have promised to collect and disclose that information in time. [email protected] Failed study spawns fresh debate about fish-oil-derived drugs for heart disease Tags Coronavirus National Biotech Reporter Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast. General Assignment Reporter Andrew covers a range of topics, from addiction to public health to genetics. The success of a second vaccine against Covid-19 means the world is a big step closer to curbing the coronavirus pandemic.Moderna, joined by U.S. government scientists, announced Monday that their mRNA vaccine candidate was 94.5% effective in preventing Covid-19, the disease caused by the novel coronavirus, according to an interim analysis of a 30,000-patient clinical trial. The news comes exactly one week after Pfizer and BioNTech said their respective Covid-19 vaccine candidate, also created using mRNA technology, was more than 90% effective in its own 60,000-patient clinical trial. Here’s what we know — and still need to learn — about the two most advanced Covid-19 vaccines and how they might reshape the pandemic that has killed 1.3 million people worldwide and infected at least 54.5 million. advertisement Related: Health experts want to prioritize people of color for a Covid-19 vaccine. But how should it be done? Why the pharma industry got lucky with Pfizer — for now Adam Feuerstein Andrew Joseph Damian Garde What does this mean for the other vaccines in development?While both the Moderna and the Pfizer/BioNTech vaccines are based on mRNA technology, the other frontrunners — from AstraZeneca and Johnson & Johnson — use different approaches. (Other companies, including Sanofi, are at work on mRNA vaccines, but their candidates are not as far along in the development process.)But all the top candidates are targeting the virus’ spike protein, which the pathogen uses to infect cells. The results from the Pfizer and Moderna trials give hope that other vaccine candidates could be effective as well, given that they’re all going after the same bull’s-eye. “Today’s announcement provides further confirmation that spike-directed vaccines can provide a protective immune response,” said Richard Hatchett, the CEO of the Coalition for Epidemic Preparedness Innovations, known as CEPI. What does this mean for mRNA?Outside of its implications for the global pandemic, the tandem success of Moderna and Pfizer’s vaccines is a massive affirmation of the promise of mRNA, a medical technology that has advanced in fits and starts for three decades.At the start of 2020, SARS-2 was a virus that had never been studied, or even known. Less than a year later, two companies have developed what appears to be an effective vaccine for it. That suggests mRNA technology can be used to rapidly design and deploy vaccines for other pathogens. In Moderna’s case, it bodes well for in-development vaccines for Zika virus and cytomegalovirus, and it supports the company’s long-term plan to get into the business of manufacturing flu vaccines each year. For Pfizer’s partner BioNTech, which is developing vaccines for cancer, HIV, and influenza, it’s similarly encouraging. What are mRNA vaccines?Volume 90%Press shift question mark to access a list of keyboard shortcutsKeyboard ShortcutsEnabledDisabledPlay/PauseSPACEIncrease Volume↑Decrease Volume↓Seek Forward→Seek Backward←Captions On/OffcFullscreen/Exit FullscreenfMute/UnmutemSeek %0-9 facebook twitter Email Linkhttps://www.statnews.com/2020/11/16/with-strong-data-on-two-covid-19-vaccines-we-have-more-answers-about-the-road-ahead-and-questions-too/?jwsource=clCopied EmbedCopiedLive00:0002:0302:03 Scientists can now design genetic material called mRNA to help us build immunity to certain viruses, including SARS-CoV-2, the coronavirus that causes Covid-19. Find out how mRNA vaccines work in this video. Hyacinth Empinado/STAT At the same time, vaccines have always been the lowest hanging fruit in the minds of mRNA researchers. The baseline promise of mRNA is that it can compel cells in the body to manufacture a specific protein, treating or preventing disease in the process. But developing mRNA medicines has always been a delicate balance: Scientists have to administer enough of the synthetic substance to ensure protein production, but not too much so as to avoid a dangerous immune reaction. Vaccines, which require only one or two doses of mRNA, are the most logical application of the technology. The bigger — and more lucrative — use for mRNA would be therapeutics for the scores of diseases that can be treated by making certain proteins in the body. That would require routine and lifelong administrations of mRNA, something neither Moderna nor BioNTech is yet to crack in a large clinical trial.When can I get a vaccine? Both Moderna and Pfizer have promised to file for emergency use authorizations in the coming weeks. If the FDA grants them, as it’s widely expected to do before the end of the year, the companies will ship doses to the federal government, which is in charge of allocating the limited supply to front-line workers and people at an elevated risk of severe Covid-19. By Adam Feuerstein , Damian Garde , and Andrew Joseph Nov. 16, 2020 Reprints @DrewQJoseph Related: [email protected] @damiangarde Related: HealthWith strong data on two Covid-19 vaccines, we have more answers about the road ahead — and questions too [email protected] Related: Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast.
AdvertisementRecommended ArticlesBrie Larson Reportedly Replacing Robert Downey Jr. As The Face Of The MCURead more81 commentsGal Gadot Reportedly Being Recast As Wonder Woman For The FlashRead more29 commentsDC Young Fly knocks out heckler (video) – Rolling OutRead more6 comments’Mortal Kombat’ Exceeded Expectations Says WarnerMedia ExecutiveRead more2 commentsDo You Remember Bob’s Big Boy?Read more1 commentsKISS Front Man Paul Stanley Reveals This Is The End Of KISS As A Touring Band, For RealRead more1 comments There’s been a lot of good news about potential coronavirus vaccines. At least three of the experimental vaccines show an impressive efficacy, according to information released by the makers in news releases.AstraZeneca reports that its vaccine prevented coronavirus infection in 62 percent of the time when people got two doses a month apart. Later, a subgroup of volunteers who got a half dose followed by a full dose a month later, the vaccine was 90 percent effective.Vaccines made by Pfizer Inc and biotechnology company Moderna appear to protect against symptomatic infection 95% of the time.Pfizer’s and Moderna’s vaccines use very similar technology, while AstraZeneca used a different approach. They are among six vaccines getting some kind of federal government support in the United States and dozens in development around the world. DOH-Collier bringing COVID-19 vaccines to homebound residents June 17, 2021 AdvertisementMost of the following vaccines are in Phase 3 clinical trials, the last step before seeking the go-ahead from the US Food and Drug Administration and other regulators around the world.Pfizer and BioNTechThis vaccine uses messenger RNA or mRNA. Mobile pediatric clinic provides COVID vaccines for children 12+ June 15, 2021 Lee County COVID-19 vaccine site moving to North Fort Myers this month June 13, 2021 Messenger RNA is a single strand of the genetic code that cells can “read” and use to make a protein. In the case of this vaccine, the mRNA instructs cells in the body to make the particular piece of the virus’s spike protein. Then the immune system sees it, recognizes it as foreign and is prepared to attack when actual infection occurs.BioNTech researchers used a little piece of genetic material coding for a piece of the spike protein — the structure that adorns the surface of the coronavirus, giving it that studded appearance.MRNA is very fragile so it’s encased in lipid nanoparticles — a coating of a buttery substance that can melt at room temperature. That’s why Pfizer’s vaccine must be kept at ultracold temperatures of about minus 100 degrees F.Special equipment will be needed to ship and store this vaccine.ModernaModerna’s vaccine is also based on mRNA. “mRNA is like software for the cell” Moderna said on its website.Moderna has come up with a different formulation for the lipid nanoparticles to protect the mRNA in its vaccine. These formulations are corporate secrets, but Moderna thinks its approach is better and said its vaccine can be shipped at minus 4 degrees F and can be kept stable for 30 days at 36 to 46F, the temperature of a standard home refrigerator.AstraZenecaAstraZeneca’s vaccine, made with a team at Britain’s Oxford University, is called a vector vaccine. It uses a common cold virus called an adenovirus to carry the spike protein from the coronavirus into cells.It’s a cheaper way to make vaccines — but slower than using RNA. The company has pledged to make its vaccine available inexpensively to countries around the world. The vaccine can be kept stable for six months at standard refrigerator temperatures, the company said.Johnson & Johnson’s vaccine arm Janssen PharmaceuticalsThis is one vaccine that has been tested on the market before. The adenovirus 26 vector was used to make the company’s Ebola vaccine, which won marketing authorization from the European Commission in July.It’s a one-shot vaccine but earlier this month Johnson & Johnson started a two-dose, Phase 3 trial in Britain, because there’s some evidence that two doses provide better protection. Volunteers will get two shots, 57 days apart, or placebos.NovavaxMaryland-based biotechnology company Novavax specializes in “protein subunit” vaccines. They use virus-like nanoparticles as a base and cover them with genetically engineered pieces of the coronavirus spike protein.A hepatitis B vaccine given to newborns is a protein subunit vaccine, as is the human papillomavirus or HPV vaccine and FluBlok, Sanofi’s influenza vaccine.Novavax uses an insect virus called a baculovirus to get the coronavirus spike protein into moth cells, which then produce the protein. This is harvested and mixed with an adjuvant — an immune booster –based on saponin, found in soap bark trees.Sanofi and GlaxoSmithKlineThis is also a protein subunit vaccine, using Sanofi’s FluBlok technology with a GlaxoSmithKline adjuvant. It also uses a baculovirus to grow little bits of spike protein. Sinovac and SinopharmChinese company Sinovac’s CoronaVac uses an inactivated virus — one of the oldest methods for vaccinating people. Whole batches of coronavirus are grown, “killed” and then made into vaccine. Likewise, Sinopharm’s vaccine in an inactivated virus.Sputnik VRussia’s Sputnik V coronavirus vaccine is an adenoviral vector vaccine. It uses two common cold viruses called adenovirus 5 and adenovirus 26 to carry the genetic material for the spike protein into the body.The-CNN-Wire™ & © 2020 Cable News Network, Inc., a WarnerMedia Company. All rights reserved. Mobile pediatric vaccination clinic happening in Cape Coral Friday June 11, 2021 AdvertisementTags: Coronaviruscovid-19 vaccineVaccine RELATEDTOPICS
Bizarre situation as Ben Brennan breaks up Fianna Fáil-Fine Gael arrangement to take Graiguecullen-Portarlington vice-chair role Ratheniska NS now accepting applications for Junior Infants for September 2021 Facebook Home Sponsored Ratheniska NS now accepting applications for Junior Infants for September 2021 Sponsored WhatsApp Electric Picnic organisers release statement following confirmation of new festival date Twitter Electric Picnic TAGSRatheniskaRatheniska NS Laois Councillor ‘amazed’ at Electric Picnic decision to apply for later date for 2021 festival News Electric Picnic Pinterest RELATED ARTICLESMORE FROM AUTHOR Previous articleUPDATED: Government confirm new elements of Level 5 as penalties to be introduced for breachesNext articleJOB VACANCY: Joe Mallon Motors seeking to hire full-time Valetor LaoisToday Reporter Ratheniska NS, located outside Portlaoise, have commenced accepting applications for admission to Junior Infants 2021.The school will cease accepting applications for admissions on November 9, 2020.Application form is available to download from www.ratheniskans.ie or on request from the school office by contacting 057 8625148.Ratheniska NS, Ratheniska, Portlaoise, Co Laois – R32 HW50.Email: [email protected] ALSO – Check out the dedicated property section on LaoisToday Twitter WhatsApp By LaoisToday Reporter – 20th October 2020 Pinterest Facebook
Patricia Chisholm Facebook LinkedIn Twitter Tax tips for self-employed clients Federal budget bill includes changes to stock options, annuities, mutual fund trusts In the case, the SCC found that an exception to solicitor-client privilege in the Income Tax Act (ITA) — which has been used by tax officials to gather information about taxpayers from their lawyers and, in Quebec, their notaries — is unconstitutional. Furthermore, the privilege does not apply only to communications between lawyers and clients, as has sometimes been argued. It also covers facts, the SCC ruled. As the decision notes, “[W]e cannot conclude … that [a lawyer’s] communications with his clients are distinct from financial records that disclose various facts about their relationships in order to determine whether solicitor-client privilege covers those facts. Absent proof to the contrary, all of this information is prima facie privileged, and therefore confidential.” The case arose when Duncan Thompson, a lawyer from a small town in Alberta, became the object of CRA enforcement action. Tax authorities sought personal financial information from Thompson, which included his accounts receivable. Although Thompson complied with some of these requests, he declined to give the CRA information that would identify his clients. After the Minister of Revenue applied to the Federal Court for a compliance order against Thompson, the lawyer objected. He argued that the information sought was subject to solicitor-client privilege and, further, that it constituted unreasonable search and seizure, contrary to Sec. 8 of the Canadian Charter of Rights and Freedoms. In a companion appeal, Canada v. Chambre des notaire, the SCC ruled that the exception under the ITA is constitutionally invalid because it violates Sec. 8 of the Charter. As a result, the SCC found that the Minister’s application against Thompson should be dismissed. However, the ruling in Thompson’s favour also includes a discussion of the nature of the solicitor-client privilege. The decision notes that: “Solicitor-client privilege has evolved from being treated as a mere evidentiary rule to being considered a rule of substance and, now, a principle of fundamental justice.” Further, the SCC’s decision notes that “an intrusion on solicitor-client privilege must be permitted only if doing so is absolutely necessary to achieve the ends of the enabling legislation.” The decision takes note of the CRA’s argument that excluding the agency’s access to the financial books and records of lawyers “could enable lawyers and their clients to hide misreporting and tax evasion behind the veil of solicitor-client privilege.” The decision also notes that it’s possible that Parliament will amend the ITA to remedy the constitutional defect of the requirement scheme. However, the decision does not address how such changes may be achieved, except to say that, in such circumstances, “a court assessing a request for access to presumptively privileged information will need to ensure that the clients whose information is being sought can participate in the process of asserting the protections that apply to them.” In a brief note on the case, Ian Humphries, a lawyer with Thorsteinssons LLP in Vancouver, noted that the pair of cases represent, “an important confirmation of the constitutional limits to the administrative powers of the CRA under the [ITA].” Photo copyright: belchonock/123RF Keywords Income taxes Clients who share tax-related information with their lawyers can have more confidence that it will not be released to the Canada Revenue Agency (CRA), according to a decision handed down by the Supreme Court of Canada (SCC) on Friday. Related news Share this article and your comments with peers on social media IRS announces filing extension for 2020 tax return
Advertisements MESSAGE BY HIS EXCELLENCY THE GOVERNOR-GENERAL FOR THE BICENTENARY COMMEMORATION OF THE ABOLITION OF THE TRANS-ATLANTIC TRADE IN ENSLAVED AFRICANS UncategorizedMarch 24, 2007 RelatedMESSAGE BY HIS EXCELLENCY THE GOVERNOR-GENERAL FOR THE BICENTENARY COMMEMORATION OF THE ABOLITION OF THE TRANS-ATLANTIC TRADE IN ENSLAVED AFRICANS FacebookTwitterWhatsAppEmail The Bicentenary Commemoration of the abolition by Great Britain of the Trans-Atlantic Trade in Enslaved Africans is without doubt a defining moment in the history and contemporary realities of Jamaica. For, it effectively cut the source of supply of the exploited labour that fed and nourished the system of slavery now universally regarded as a “crime against humanity”.The Abolition of the Trade in Enslaved Africans, lest we forget, did not bring an end immediately to the indecency of dehumanisation of millions severed from ancestral homes, to labour as chattels in the canefields of Jamaica and the rest of the British West Indies.Nor did it cut off supplies to the rest of the Americas including the United States, Cuba and Brazil. Rather, the degradation, despair, the denigration of things African, the wanton exploitation and extreme punitive measures against surrogate beasts of burden on plantations and plot, continued unabated for many years later. In 1838 “full free”, as our forebears described that Second Abolition, marked the legal extinction from Jamaican reality that debilitating practice of man’s inhumanity to man.But the first Abolition – that of the Trans-Atlantic Slave Trade – did prepare our forebears to deepen and maintain the struggle against the indecency on this side of the Middle Passage. They fought for the attainment of freedom both under law and for us to be the architects of our own fortunes. Those struggles allowed us to determine the direction and the courses of action that can take us into civil society capable of coping with the third millennium.Between 1807 and 1838, the process of creating an indigenous culture by the native-born slaves certainly helped to hone and develop the sources of resilience and determination to stake their claims as members of the human family.So years before the abolition of trade, many historians will recall, the response of a great Haitian leader to the then President of France, “It is not a circumstantial liberty conceded to us that we wish but the unequivocal adoption of the principle that no man whether he is born red, black or white can become the property of his fellow man”.Such is the spirit in which the abolition of the Trans-Atlantic Slave Trade, perpetuated to have certain human beings become the property of others, must be seen. It allowed all who came to Jamaica and the rest of the English-speaking Caribbean itself to enter a society after the abolition of slavery not as slaves dragged from homelands India and China as slaves, but as free men and women. They came not as property of other men but as contract workers under strict rules of engagement, as indentured servants without undue denial of fundamental rights to their personal liberty and cultural heritage.It is in this sense that the bicentenary commemoration must be seen as all-inclusive and all-embracing. For what it has resulted in, wittingly or unwittingly, are the building of a nation and the shaping of a society rooted in cultural diversity and the continuing quest for a society among us all regardless of race, colour, political affiliation or creed. And I might add, regardless of gender since our women ever since Nanny of the Maroons, have remained critical to our collective and individual identity, growth and development as every Jamaican son, spouse or partner will agree.The bicentenary commemoration is significant to us because the legacy of slavery continues to force into memory the urgent need to forget our history. This history could be in danger of being repeated if we fail to pluck from the jaws of the despair of the past, a future of hope that lies within our grasp.Such hope admittedly lies in the acknowledgement by the transgressors of their obligation to repair the damage done in that past with its imposition of a threatening sense of loss and chronic deprivation. This is in large measure the point of those who advocate reparations. But the hope lies even more in the conscious vigorous mobilisation of our creative energies in the spirit of the 1937 Garveyite injunction, that only we ourselves can free our minds from mental slavery which is part of the legacy that still fuels embers of self-doubt and sometimes rage.So even while we commemorate, we need to pay ancestral homage to forebears who left us another legacy, namely the love of freedom, a sense of self, and a claim to our humanity which we, as Jamaicans, have all come to treasure as fundamental to our collective empowerment and individual existence.For as is well known it is our forebears before and after 1807, who made it possible for us now to be creative participants in the challenging process of shaping a new habitable society and building a modern viable nation inhabited by an aggregation of souls who can be sure of themselves, proud of our heritage and committed to tolerance, mutual trust and that characteristic assertiveness without rancour.It behooves us all to remember, to commemorate and engage all aspects of history supportive of our endurance and liberation. For as an African proverb goes, “Until the lions have their own historians, tales of the hunt will always glorify the hunter.”It is no less significant then, that a National Committee – non-partisan and dedicated – should have been set up to plan and promote here in Jamaica the observance of this defining point in our rich, engaging and challenging history. RelatedMESSAGE BY HIS EXCELLENCY THE GOVERNOR-GENERAL FOR THE BICENTENARY COMMEMORATION OF THE ABOLITION OF THE TRANS-ATLANTIC TRADE IN ENSLAVED AFRICANS RelatedMESSAGE BY HIS EXCELLENCY THE GOVERNOR-GENERAL FOR THE BICENTENARY COMMEMORATION OF THE ABOLITION OF THE TRANS-ATLANTIC TRADE IN ENSLAVED AFRICANS